Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination

ABSTRACT Tumor immune escape is a critical problem which frequently accounts for the failure of therapeutic tumor vaccines. Among the most potent suppressors of tumor immunity are myeloid derived suppressor cells (MDSCs). MDSCs can be targeted by all-trans-retinoic-acid (atRA), which reduced their numbers and increased response rates in several vaccination studies. However, not much is known about the optimal administration interval between atRA and the vaccine as well as about its mode of action. Here we demonstrate in 2 different murine tumor models that mice unresponsive to a therapeutic vaccine harbored higher MDSC numbers than did responders. Application of atRA overcame MDSC-mediated immunosuppression and restored tumor control. Importantly, atRA was protective only when administered 3 d after vaccination (delayed treatment), whereas simultaneous administration even decreased the anti-tumor immune response and reduced survival. When analyzing the underlying mechanisms, we found that delayed, but not simultaneous atRA treatment with vaccination abrogated the suppressive capacity in monocytic MDSCs and instead caused them to upregulate MHC-class-II. Consistently, MDSCs from patients with colorectal carcinoma also failed to upregulate HLA-DR after ex vivo treatment with TLR-ligation. Overall, we demonstrate that atRA can convert non-responders to responders to vaccination by suppressing MDSCs function and not only by reducing their number. Moreover, we identify a novel, strictly time-dependent mode of action of atRA to be considered during immunotherapeutic protocols in the future.

[1]  Lisa M. Ebert,et al.  Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy? , 2017, Clinical & translational immunology.

[2]  P. Rosenstiel,et al.  Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. , 2016, Immunity.

[3]  R. Weissleder,et al.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.

[4]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[5]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[6]  M. Vetizou,et al.  Cancer and the gut microbiota: An unexpected link , 2015, Science Translational Medicine.

[7]  J. Berzofsky,et al.  Vaccine-induced myeloid cell population dampens protective immunity to SIV. , 2014, The Journal of clinical investigation.

[8]  C. Meyer,et al.  Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab , 2014, Cancer Immunology, Immunotherapy.

[9]  Tom C. Freeman,et al.  Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation , 2014, Immunity.

[10]  F. Marincola,et al.  Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment , 2013, Science.

[11]  Eric Vivier,et al.  The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide , 2013, Science.

[12]  Jun Jiang,et al.  CpG oligodeoxynucleotide induces bone marrow precursor cells into myeloid-derived suppressor cells. , 2013, Molecular medicine reports.

[13]  H. Gevensleben,et al.  Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. , 2013, Journal of hepatology.

[14]  F. Fazio,et al.  Clinical and immunologic responses in melanoma patients vaccinated with MAGE‐A3‐genetically modified lymphocytes , 2013, International journal of cancer.

[15]  Dung-Tsa Chen,et al.  Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer , 2013, Cancer Immunology, Immunotherapy.

[16]  G. Willimsky,et al.  Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. , 2013, Blood.

[17]  C. Loddenkemper,et al.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. , 2013, The Journal of clinical investigation.

[18]  D. Klinman,et al.  Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells , 2012, The Journal of Immunology.

[19]  P. Allavena,et al.  Immunology in the clinic review series; focus on cancer: tumour‐associated macrophages: undisputed stars of the inflammatory tumour microenvironment , 2012, Clinical and experimental immunology.

[20]  H. Wagner,et al.  Chemokines: A New Dendritic Cell Signal for T Cell Activation , 2011, Front. Immun..

[21]  M. Manns,et al.  Myeloid derived suppressor cells in human diseases. , 2011, International immunopharmacology.

[22]  M. Manns,et al.  Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. , 2011, Blood.

[23]  S. Endres,et al.  CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice , 2011, Clinical Cancer Research.

[24]  E. Kostareli,et al.  Efficient Treg depletion induces T‐cell infiltration and rejection of large tumors , 2010, European journal of immunology.

[25]  C. Loddenkemper,et al.  Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. , 2010, Cancer research.

[26]  C. Kurts,et al.  Cross-priming in health and disease , 2010, Nature Reviews Immunology.

[27]  Thomas Quast,et al.  Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell–licensed DCs , 2010, Nature Immunology.

[28]  M. Manns,et al.  Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC , 2010, Journal of immunotherapy.

[29]  M. Manns,et al.  Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor , 2009, Hepatology.

[30]  P. Sinha,et al.  Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1 , 2009, The Journal of Immunology.

[31]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[32]  L. Fang,et al.  Immunotherapy for advanced melanoma. , 2008, The Journal of investigative dermatology.

[33]  B. Lim,et al.  Retinoic Acid Increases Foxp3+ Regulatory T Cells and Inhibits Development of Th17 Cells by Enhancing TGF-β-Driven Smad3 Signaling and Inhibiting IL-6 and IL-23 Receptor Expression1 , 2008, The Journal of Immunology.

[34]  H. Stein,et al.  Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness , 2008, The Journal of experimental medicine.

[35]  M. Manns,et al.  A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. , 2008, Gastroenterology.

[36]  E. Tartour,et al.  Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients , 2008, Journal of immunotherapy.

[37]  L. Mariani,et al.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Neuberg,et al.  Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell , 2007, Clinical Cancer Research.

[39]  E. Tartour,et al.  Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses , 2006, Clinical Cancer Research.

[40]  Bin Yu,et al.  All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. , 2003, Cancer research.

[41]  D. Gabrilovich,et al.  Immature myeloid cells and cancer-associated immune suppression , 2002, Cancer Immunology, Immunotherapy.

[42]  V. Barak,et al.  Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response. , 1992, Immunology letters.

[43]  D. Crowther,et al.  Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. , 1977, British Journal of Cancer.